Ascentage Pharma (AAPGV) - EV/EBITDA Multiple
The macro resilience of Ascentage Pharma Group (AAPGV) is based on the non-cyclical nature of oncology research, as clearly demonstrated by the company's EV/EBITDA ratio on the financial timeline, where the current level is around 0.00. The reliability of temperature-sensitive drug logistics minimizes operational risks, while patent protection for apoptosis inhibitors creates a powerful barrier for competitors, ensuring a long-term advantage in the biotech sector.
AAPGV (ascentage.com): analytical breakdowns and indicator data
- stock price and consensus target price:
- market capitalization indicators:
- issuer book value statistics:
- debt level and financial liquidity data:
Total Debt to Capital Ascentage Pharma Group|AAPGV - Long-Term Liabilities to Capital|Short-Term Debt to Capital Ascentage Pharma|AAPGV - Company Aggregate Debts|Debt to Book Capitalization Ratio Ascentage|AAPGV - Long-Term Debt Volume|Company Short-Term Debts Ascentage Pharma|Quick Ratio ascentage.com
- net income and valuation multiples indicators:
AAPGV - Company Net Income|Expected Profit Ascentage Pharma Group|AAPGV - Price to Earnings Multiple|Projected Price to Earnings Ascentage Pharma Group|AAPGV - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Ascentage|AAPGV - Operating profit EBITDA|Net earnings per share (EPS TTM) Ascentage Pharma|AAPGV - Net earnings per share for the trailing year|Quarterly EPS earnings growth ascentage.com|AAPGV - Earnings per share growth rate in current year|Expected earnings per share growth for next year Ascentage Pharma Group
Fundamental company analysis:AAPGV (Ascentage Pharma Group Ltd)
For the biopharmaceutical sector of Ascentage Pharma Group (AAPGV), where capital-intensive cancer therapy development requires significant investment, the EV/EBITDA valuation level serves as a key indicator of sustainability. This multiple compares the total enterprise value with its operating profit before interest, taxes, depreciation, and amortization. The ratio of total value to EBITDA allows investors to assess the real value of assets relative to the company's ability to generate cash flow amidst high debt obligations.
Analysis of competing companies
BeiGene Corp - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation HALO|Revolution Medicines - EV/EBITDA Multiple|ascentage.com (AAPG) - Enterprise Value to EBITDA Ratio|CGON (CG Oncology) - Enterprise Value to EBITDA Ratio|UroGen Pharma Ltd (URGN) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bicara Bio|PSNL: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ERAS|DCTH - Company Value to EBITDA|EV/EBITDA Multiple YMAB (Y-mAbs Therapeutics, Inc.)|EV/EBITDA Multiple Aura Biosciences Inc AURA|CADL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Accuray, Inc. ARAY|SLS: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio actuatetherapeutics.com|CTOR (Citius Oncology) - EV/EBITDA Multiple|Company Value to EBITDA TuHURA HURA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protara (TARA)|Fate Pharma - Enterprise Value to Operating Income Before Depreciation|Aadi Bioscience - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio TCRX (TScan Therapeutics Inc)|Champions Oncology Corp - EV/EBITDA Multiple|XBIT - EV/EBITDA Multiple|CVM: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple OS Therapies, Inc. OSTX|RADX (Radiopharm Theranostics) - EV/EBITDA Multiple|Company Value to EBITDA Artiva ARTV|Enterprise Value to EBITDA Ratio ANL (Adlai Nortye Ltd.)|VERU (Veru Inc) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tempest Tx TPST|XLO (Xilio Therapeutics Inc) - Company Value to Operating Income Before Depreciation Ratio|Enochian BioSciences - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation MURA (Mural Oncology plc)|KAPA: EV/EBITDA Multiple|OnKure Therapeutics (OKUR) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CytoMed Therapeutics Ltd|CRIS: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Apollomics, Inc. (APLM)|Enterprise Value to EBITDA Ratio tharimmune.com THAR|EV/EBITDA Multiple ADVB (Advanced Biomed)|EV/EBITDA Multiple Genprex Inc. GNPX|CLDI: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation SBFM (sunshinebiopharma.com)|XBIO: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple salariuspharma.com SLRX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Purple Biotech Ltd.|AONC: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BeOne Medicines (BGNE)|CKPT - Company Value to EBITDA|Elevation Oncology - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple iCAD Inc. ICAD|IKNA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio NTBL|VIRX: EV/EBITDA Multiple|MorphoSys Corporation (MOR) - EV/EBITDA Multiple|NAYA (NAYA Biosciences) - EV/EBITDA Multiple
